Molecular conjugates comprising human monoclonal antibodies to dendritic cells
Molecular conjugates comprising an antigen linked to a human monoclonal antibody that specifically binds to dendritic cells are disclosed. Also disclosed are pharmaceutical compositions comprising the molecular conjugates and therapeutic methods for using the conjugates.
1. A molecular conjugate comprising a human monoclonal antibody that binds to human dendritic cells, linked to an antigen, wherein the antibody comprises heavy chain and light chain variable regions which comprise the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4, respectively.
2. A molecular conjugate comprising a monoclonal antibody that binds to the human macrophage mannose receptor, linked to Pmel-17 antigen, wherein the antibody comprises heavy chain and light chain variable regions which comprise the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4, respectively.
3. A molecular conjugate comprising a monoclonal antibody that binds to the human macrophage mannose receptor, linked to Pmel-17 antigen, wherein the molecular conjugate is encoded by the nucleotide sequence shown in SEQ ID NO:8.
4. A molecular conjugate comprising a monoclonal antibody that binds to the human macrophage mannose receptor, linked to NY-ESO-1 antigen, wherein the antibody comprises heavy chain and light chain variable regions which comprise the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4, respectively.
5. A composition comprising a molecular conjugate according to claim 1 , 2 , 3 or 4 , and a pharmaceutically acceptable carrier.
6. The composition of claim 5 further comprising an adjuvant.
7. The molecular conjugate of claim 1 , wherein the antibody binds to the human macrophage mannose receptor.
8. The molecular conjugate of claim 1 , produced as a recombinant fusion protein or a chemical conjugate.